HC Wainwright Issues Pessimistic Forecast for Keros Therapeutics (NASDAQ:KROS) Stock Price

Keros Therapeutics (NASDAQ:KROS - Free Report) had its target price cut by HC Wainwright from $47.00 to $40.00 in a research note issued to investors on Thursday morning,Benzinga reports. They currently have a buy rating on the stock.

KROS has been the topic of several other reports. TD Cowen lowered Keros Therapeutics from a "buy" rating to a "hold" rating in a research note on Thursday, December 12th. William Blair downgraded shares of Keros Therapeutics from an "outperform" rating to a "market perform" rating in a report on Thursday, December 12th. Cantor Fitzgerald lowered shares of Keros Therapeutics from an "overweight" rating to a "neutral" rating in a research report on Tuesday, January 21st. BTIG Research lowered shares of Keros Therapeutics from a "buy" rating to a "neutral" rating in a research report on Thursday, December 12th. Finally, Wells Fargo & Company raised their price objective on shares of Keros Therapeutics from $88.00 to $111.00 and gave the stock an "overweight" rating in a report on Wednesday, December 11th. Six research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Keros Therapeutics has an average rating of "Moderate Buy" and an average price target of $42.33.

Keros Therapeutics Stock Up 0.2 %

Keros Therapeutics stock traded up $0.02 during mid-day trading on Thursday, reaching $11.10. 935,979 shares of the company's stock were exchanged, compared to its average volume of 1,606,921. The business's fifty day simple moving average is $12.52 and its 200 day simple moving average is $39.49. Keros Therapeutics has a one year low of $9.77 and a one year high of $72.37. The firm has a market capitalization of $449.63 million, a PE ratio of -2.13 and a beta of 1.39.

Remove Ads

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last released its earnings results on Wednesday, February 26th. The company reported ($1.14) earnings per share for the quarter, beating analysts' consensus estimates of ($1.36) by $0.22. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The firm had revenue of $3.04 million for the quarter, compared to analysts' expectations of $37.32 million. On average, sell-side analysts forecast that Keros Therapeutics will post -4.74 earnings per share for the current year.

Hedge Funds Weigh In On Keros Therapeutics

Several institutional investors have recently modified their holdings of the company. Braidwell LP boosted its stake in Keros Therapeutics by 167.9% in the fourth quarter. Braidwell LP now owns 1,894,439 shares of the company's stock worth $29,989,000 after buying an additional 1,187,199 shares in the last quarter. Point72 Asset Management L.P. lifted its stake in shares of Keros Therapeutics by 155.9% in the 3rd quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company's stock valued at $55,025,000 after acquiring an additional 577,220 shares during the last quarter. Lynx1 Capital Management LP bought a new position in shares of Keros Therapeutics in the fourth quarter worth approximately $8,612,000. Millennium Management LLC grew its holdings in Keros Therapeutics by 53.3% in the 4th quarter. Millennium Management LLC now owns 878,159 shares of the company's stock worth $13,901,000 after acquiring an additional 305,169 shares during the last quarter. Finally, Alkeon Capital Management LLC grew its stake in shares of Keros Therapeutics by 18.7% in the third quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company's stock worth $110,194,000 after purchasing an additional 298,694 shares during the last quarter. 71.56% of the stock is currently owned by institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.